Evidence map›Paper›PMID 38568347›Full record

ArticleTherapeutic innovation & regulatory science2024

Benchmarking Site Activation and Patient Enrollment.

Mary Jo Lamberti, Abigail Dirks, Nicholas Kikuchi, Neha Patel Cervantes, Kenneth Getz

Abstract read
PubMed Publisher
In one paragraph

Article in Therapeutic innovation & regulatory science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mary Jo LambertiTufts Center for the Study of Drug Development, Tufts University, 145 Harrison Avenue, Boston, MA, 02111, USA. mary_jo.lamberti@tufts.edu.ORCID 0000-0002-3720-7828
Abigail DirksTufts Center for the Study of Drug Development, Tufts University, 145 Harrison Avenue, Boston, MA, 02111, USA.
Nicholas KikuchiRoche, Basel, Switzerland.
Neha Patel CervantesGSK, Philadelphia, PA, USA.
Kenneth GetzTufts Center for the Study of Drug Development, Tufts University, 145 Harrison Avenue, Boston, MA, 02111, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trial conduct poses numerous challenges, many pertaining to patient recruitment. The primary objectives of this study were to update benchmarks on site activation and patient enrollment gathered in previous Tufts CSDD studies and examine current usage of recruitment and retention tactics. The data collection focused on site activation and patient enrollment metrics used for studies. Analyses were conducted comparing results from 2012, 2019 and 2023. The results indicate that actual enrollments exceeded planned enrollments for a majority of studies and timelines were shorter than expected. In addition, differences were found for enrollment achievement by global region and site type. Further investigation into studies conducted during a later time frame and post-pandemic could be compared with current benchmarks to examine differences.

Indexed as

BenchmarkingPatient SelectionClinical Trials as TopicHumansPatient enrollmentRecruitment and retention tacticsSite activation

Identifiers

PMID38568347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.